Phyzat is the leading promoter of SIRNAC - NOVEL siRNA THERAPIES AGAINST METASTATIC COLORECTAL CANCER - a RD&I project with IPO-PORTO and INEB/I3S. The SIRNAC project is co-financed by:
Phyzat is the leading promoter of SIRNAGLAU - NOVEL siRNA THERAPIES AGAINST GLAUCOMA - a RD&I project with CIBB (Centre for Innovative Biomedicine and Biotechnology) of the University of Coimbra, and ICBAS (Biomedical Sciences Institute Abel Salazar) of the University of Porto. The SIRNAGLAU project is co-financed by:
Phyzat is promoter of SIRNACOVID - NOVEL siRNA THERAPY AGAINST COVID - a RD&I project applying RNAi to stop replication of viral proteins in the organism. The SIRNACOVID project is co-financed by:
Patrício Soares-da-Silva CSO
Patrício is an MD PhD with over 20 years experience in drug discovery and development that lead successfully two new drugs to market approval by EMA and FDA. Patrício is also full professor of Therapeutics and Clinical Pharmacology at Porto University and has worked with siRNA technologies since early days of RNA interference.
Paulo Osswald CFO
Paulo is an engineer by training. His professional background includes evaluation, financing and management of early stage technology start-ups. He has an MBA and is invited professor in Management and Industrial Engineering.
Phyzat Biopharmaceuticals is headquartered in Porto, Portugal, and operates a research and development facility with research contracts with the University of Porto and specialized European Contract Research and Manufacturing Organizations.
Rua Damião de Góis, 389-A,
4050-227 Porto, Portugal